CASI Pharmaceuticals Gets FDA Approval For Investigational New Drug CID-103 In Treating Immune Thrombocytopenia (ITP).

Ractigen Therapeutics Gains NMPA Clearance to Begin Phase 1 Trials of RAG-17 in Chinese SOD1-ALS Patients.

With Weekly Dosing, Insulin Efsitora Alfa Achieves A1C Reduction and Matches Safety of Daily Insulin.

Ionis Pharmaceuticals, Inc. reported favorable primary results from the HALOS Phase 1/2a open-label trial of ION582 for Angelman syndrome.

Ionis Pharmaceuticals, Inc. and Biogen Inc. have decided to discontinue the development of BIIB105 (ION541) following the initial outcomes from the Phase 1/2 ALSpire trial.

Carisma Therapeutics reports initial patient dosed in Phase 1 study of CT-0525, an innovative HER2-focused CAR-monocyte therapy.

The FDA has greenlit Imdelltra™ (tarlatamab-dlle), marking the first T-cell engager therapy for extensive-stage small cell lung cancer.

Proteologix’s lineup includes PX128, a bispecific antibody that targets both IL-13 plus TSLP. PX128 is poised to advance into phase 1 development for the treatment of moderate to severe atopic dermatitis and asthma.

Bayer Begins Phase I Trial of 225Ac-PSMA-Trillium Targeted Radionuclide Therapy for Advanced Metastatic Prostate Cancer.

The U.S. FDA has approved Bristol Myers Squibb's CAR T cell therapy Breyanzi for treating relapsed or refractory follicular lymphoma.

Genentech Announces Favorable Phase Ib Outcomes for Dual GLP-1/GIP Receptor Agonist CT-388 in Obesity Patients.

A2 Biotherapeutics has reported the administration of the initial dose to the first participant in the Phase 1 clinical trial of A2B694.